The effect of necitumumab in combination with gemcitabine-cisplatin on health-related quality of life (HRQOL) and tolerability: squire trial patients with epidermal growth factor receptor (EGFR)-expressing squamous NSCLC tumours.
Authors
Reck, MSocinski, M
Szczesna, A
Dediu, M
Ramlau, R
Losonczy, G
Molinier, O
Schumann, C
Brown, J
Soldatenkova, V
Chouaki, N
Thatcher, Nick
Luft, A
Affiliation
Department of Thoracic Oncology, ARCN, Grosshandsdorf, GermanyIssue Date
2016-11
Metadata
Show full item recordCitation
The effect of necitumumab in combination with gemcitabine-cisplatin on health-related quality of life (HRQOL) and tolerability: squire trial patients with epidermal growth factor receptor (EGFR)-expressing squamous NSCLC tumours. 2016, 19(7):A748-A749 Value in HealthJournal
Value in HealthDOI
10.1016/j.jval.2016.09.2296Additional Links
http://linkinghub.elsevier.com/retrieve/pii/S1098301516336622Type
Meetings and ProceedingsLanguage
enISSN
10983015ae974a485f413a2113503eed53cd6c53
10.1016/j.jval.2016.09.2296